Literature DB >> 11289280

Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer.

K Johnson1, A Bakhsh, D Young, T E Martin, M Arnold.   

Abstract

INTRODUCTION: Several studies have been performed comparing computed tomography scan with positron emission tomography scan in clinical decision making. Unfortunately, therapeutic decisions are being made based on positron emission tomography scan data without a clear understanding of how well the diagnostic findings correlate with the clinical findings.
METHODS: A retrospective review of 41 patients with metastatic colorectal cancer was performed. All patients had both a computed tomography scan and a positron emission tomography scan before surgical exploration. All underwent surgical re-exploration. Findings were divided into hepatic, extrahepatic, and pelvic regions of the abdomen. Computed tomography scan and positron emission tomography scan findings were either confirmed or refuted by the operative findings.
RESULTS: Positron emission tomography scan was found to be more sensitive than computed tomography scan when compared with actual operative findings in the liver (100 vs. 69 percent, P = 0.004), extrahepatic region (90 vs. 52 percent, P = 0.015), and abdomen as a whole (87 vs. 61 percent, P < 0.001). Sensitivities of positron emission tomography scan and computed tomography scan were not significantly different in the pelvic region (87 vs. 61 percent, P = 0.091). In each case, specificity was not significantly different between the two examinations.
CONCLUSION: Computed tomography scan and positron emission tomography scan are both diagnostic tests useful in the evaluation of metastatic colorectal cancer. However, positron emission tomography scanning is more sensitive than computed tomography scanning and more likely to give the correct result when actual metastatic disease is present.

Entities:  

Mesh:

Year:  2001        PMID: 11289280     DOI: 10.1007/bf02234732

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

Review 1.  Treatment for multiple bilobar liver metastases of colorectal cancer.

Authors:  Hiroshi Shimada; Kuniya Tanaka; Kenichi Matsuo; Shinji Togo
Journal:  Langenbecks Arch Surg       Date:  2005-12-01       Impact factor: 3.445

2.  Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.

Authors:  H Furukawa; H Ikuma; A Seki; K Yokoe; S Yuen; T Aramaki; S Yamagushi
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

3.  Early colon cancer detected by 18F-FDG PET.

Authors:  Kazuhiro Sakamoto; Makoto Takahashi; Yukihiro Yaginuma; Yasunori Ishido; Takashi Matsuoka; Shuichi Sakamoto; Yuichi Tomiki; Toshiki Kamano
Journal:  Int J Gastrointest Cancer       Date:  2005

4.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 5.  Advances in the management of rectal cancer.

Authors:  D Lawes; P B Boulos
Journal:  J R Soc Med       Date:  2002-12       Impact factor: 18.000

6.  What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer.

Authors:  Monique Maas; Iris J G Rutten; Patty J Nelemans; Doenja M J Lambregts; Vincent C Cappendijk; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-06       Impact factor: 9.236

7.  FDG-PET in colorectal cancer.

Authors:  Lioe-Fee de Geus-Oei; Theo J M Ruers; Cornelis J A Punt; Jan Willem Leer; Frans H M Corstens; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.